Drug Profile
HBN 1
Alternative Names: HBN-1Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator University of North Carolina
- Developer Hibernaid; University of North Carolina
- Class Anti-ischaemics; Heart failure therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Brain injuries; Heart arrest; Sepsis; Spinal cord injuries; Stroke
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Brain injuries in USA (IV) (Hibernaid pipeline, August 2023)
- 31 Aug 2023 Discontinued - Preclinical for Heart arrest in USA (IV) (Hibernaid pipeline, August 2023)
- 31 Aug 2023 Discontinued for Sepsis in USA (IV) (Hibernaid pipeline, August 2023)